InMed Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 4/6
InMed Pharmaceuticals has a total shareholder equity of $9.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $11.8M and $2.6M respectively.
Anahtar bilgiler
0%
Borç/özkaynak oranı
US$0
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$6.61m |
| Eşitlik | US$9.21m |
| Toplam yükümlülükler | US$2.62m |
| Toplam varlıklar | US$11.82m |
Son finansal sağlık güncellemeleri
Recent updates
InMed Pharmaceuticals GAAP EPS of -$33.17, revenue of $1.09M
Sep 26InMed Pharma announces $6M private placement
Sep 09InMed Pharma says phase 2 trial for skin disorder cannabinol cream can now include teens
Jul 25InMed Pharmaceuticals gets non-compliance notice on Nasdaq minimum bid price requirement
Jul 13InMed To Acquire Rare Cannabinoid Manufacturer BayMedica
Jul 02InMed's INM-755 CBN cream did not introduce any delay in normal wound healing
Jan 08Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: INM's short term assets ($8.7M) exceed its short term liabilities ($2.0M).
Uzun Vadeli Yükümlülükler: INM's short term assets ($8.7M) exceed its long term liabilities ($644.9K).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: INM is debt free.
Borcun Azaltılması: INM had no debt 5 years ago.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: INM has less than a year of cash runway based on its current free cash flow.
Tahmini Nakit Akışı: INM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.8% each year